Unfortunately, a triple-negative breast cancer cell line, MDA-MB-231, which is known to overexpress EGFR [26], showed a refractory phenotype as well as no obvious change in EGFR levels in response to the co-treatment. Here, EGFR is linked to triple-negative breast carcinoma.